Medtronic has announced CE mark receipt and the European launch of its newest cardiac resynchronisation therapy-pacemaker, Viva CRT-P. The Viva CRT-P is not approved for sale in the United States.
According to a company release, the Viva CRT-P includes the Medtronic-exclusive AdaptivCRT software, which is the only algorithm demonstrated to improve heart failure patients’ response to the therapy and reduce the risk of atrial fibrillation (as compared to conventional biventricular therapy).
The AdaptivCRT algorithm works by preserving normal heart rhythms and automatically adjusting to the patient’s needs every minute, creating a customised therapy for each patient. Independent studies have validated the benefits of the algorithm, including:
- AdaptivCRT increases CRT response rate by 12%;
- Patients with AdaptivCRT have a demonstrated 21% reduction in heart failure hospitalisation and a reduced risk of death;
- Patients with AdaptivCRT have a 46% reduced risk of atrial fibrillation.
Viva CRT-P also features advanced diagnostics tools, such as OptiVol fluid status monitoring and Cardiac Compass Report, which provide unmatched levels of insight into patients’ physiological condition. These tools are proven to identify patients at risk for rehospitalisation within 30 days of discharge, a critical quality measure.
“The diagnostic capabilities of this smart device help improve function throughout the continuum of care,” says David Steinhaus, vice president and general manager, Heart Failure, and medical director for the Cardiac Rhythm Disease Management business at Medtronic. “This represents a win for both patients and physicians and, when coupled with additional longevity, provides another layer of distinct value over a longer period.”